Format

Send to

Choose Destination
Nagoya J Med Sci. 2016 Dec;78(4):399-406. doi: 10.18999/nagjms.78.4.399.

A multicenter survey of stage T1 glottic cancer treated with radiotherapy delivered in 2.25-Gy fractions in clinical practice: An initial 5-year analysis.

Author information

1
Department of Radiology Nagoya University Graduate School of Medicine, Nagoya, Japan.
2
Department of Radiology Mie University Graduate School of Medicine, Tsu, Japan.
3
Department of Radiation Oncology Ichinomiya Municipal Hospital, Ichinomiya, Japan.
4
Department of Radiology Tosei General Hospital, Seto, Japan.
5
Department of Radiology Toyohashi Municipal Hospital, Toyohashi, Japan.
6
Department of Radiation Oncology Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan.
7
Department of Radiation Oncology Gifu Prefectural Tajimi Hospital, Tajimi, Japan.
8
Department of Radiation Oncology Nakatsugawa City Hospital, Nakatsugawa, Japan.

Abstract

The purpose of this study was to evaluate the acute and late toxicity as well as local control (LC) in T1 glottic cancer (GC) patients treated with hypofractionated radiotherapy (RT) in clinical practice. The Tokai Study Group for Therapeutic Radiology and Oncology started RT treatment with a dose of 2.25 Gy for T1 GC in 2011. Ten institutions combined data from 104 patients with T1 squamous cell carcinoma between 2011 and 2015. In total, 104 patients with T1 GC were irradiated with a standard radiation dose of 63 Gy in 28 fractions.The median follow-up duration was 18 (3.7-49.5) months. Acute grade 3 adverse events were observed in 7 patients, with 4 patients (5%) having dermatitis and 3 patients (4%) having mucositis. Late adverse events above grade 3 were not observed. Two patients developed local recurrence. The rates of acute adverse events in the present study were comparable to those in previous studies that have used 2 Gy fractions of RT.

KEYWORDS:

T1 glottic cancer; fraction size; hypofractionation; radiotherapy

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center